MedTrace Logo

Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

NCT05649579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 146

Last updated 2023-12-04

No results posted yet for this study

Summary

This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.

Conditions

  • Bullous Pemphigoid

Interventions

DRUG

Dupilumab

Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Second Xiangya Hospital of Central South University

    collaborator OTHER

  • Shandong Provincial Institute of Dermatology and Venereology

    collaborator OTHER

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Mingyue Wang · Peking University First Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2022-12-31
Completion
2023-01-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05649579 on ClinicalTrials.gov